Answers are grounded in this paper and cite their sources.
This editorial refers to the article ‘Patient–physician discordance in assessing SLE disease activity: longitudinal analysis of disease-related variables and quality of life’ by Agner R Parra Sánchez et al. 2026; doi: 10.1093/rheumatology/keaf653. To understand and manage a disease as multifaceted as SLE, rigorous and nuanced disease evaluation is fundamental. Clinically, SLE can affect virtually all organ systems, with variable severity and unpredictable courses, rendering disease assessment a complex undertaking. This complexity is reflected by the multitude of instruments—often used in combination—to measure physician-reported disease activity, as well as in the well-documented discrepancies between patient and physician assessments [1]. Far from being a methodological inconvenience, these discrepancies raise fundamental questions about how disease activity and treatment goals are conceptualized and prioritized in SLE care. The study by Parra-Sánchez et al. offers insightful analyses that deepen our understanding of these patient–physician discrepancies [2]. Leveraging longitudinal data from the Amsterdam SLE cohort, Parra-Sánchez et al. characterized discordances between patient global assessment (PaGA) and physician global assessment (PGA), both scored on a 0–10 scale, over 5 years. Additionally, they identified determinants of discrepancy and examined how PaGA discordance aligns with the Definitions of Remission in SLE (DORIS) criteria. Among 193 adults with SLE contributing to 650 annual visits, discordance—defined as a ≥2-point difference between PaGA and PGA—occurred in over half of the visits (55.3%). In the vast majority of cases, patients rated their disease as more active than their physicians. Viewed from another angle, among visits meeting DORIS remission criteria, more than one-third of patients recorded a PaGA ≥ 3. Beyond these striking figures, the study provides insights into the magnitude and variation of discordance over time. On average, patients rated their disease 1.6 points higher than their physicians. The distribution of discordance varied across levels of disease activity, with higher concordance when patients perceived their disease as controlled. When examining changes over time, in visits with a ≥2-point increase or decrease in PGA compared with the previous visit (interpretable as worsening or improvement, respectively), PaGA changed in the same direction in only 57% of visits, reflecting limited agreement in the perception of change. These findings prompt a critical question: what do these discrepancies represent? Several non-mutually exclusive explanations may account for patient–physician discordance. First, as documented across inflammatory arthropathies [3], discordance may reflect differences in the underlying constructs being assessed: physicians focus on inflammatory disease activity while patients tend to evaluate disease impact. Data from the study by Parra-Sánchez et al. support this notion, including associations between PaGA and health-related quality of life as measured by SF-36 (particularly bodily pain and vitality) as well as differing distributions of SLEDAI-2K domains. Patients rating their disease as more active than their physicians were often more active in the musculoskeletal (22%) and mucocutaneous (19%) domains, whereas those rating their disease as less active predominantly had serological (21%) and renal (19%) activity. These patterns suggest that different types of discordance carry distinct implications: while the former risks under-recognition of patient-relevant symptoms, the latter may lead to reduced medication adherence in the context of clinically significant but asymptomatic disease. Discrepancies may also arise from methodological differences between PGA and PaGA, including scale range (e.g. 0–3, 10, or 100), timeframe of assessment (e.g. 1–4 weeks), and the use of explicit anchors. Efforts to standardize these measures, building on recent consensus recommendations for PGA [4], and ensuring better alignment between patient- and physician-reported assessments, are therefore warranted. Discordance may also reflect deeper differences in how key disease states are conceptualized by patients and physicians. This interpretation is supported by data from the 2024 Living with Lupus survey, led by Lupus Europe [5]. When asked to define disease control, patients most frequently cited ‘normal blood tests/my doctor tells me the disease is under control’ (41%), ‘no flares for ≥6 months’, and ‘stable medications and no flares’ (36% each). These findings illustrate that patients’ expectations extend beyond inflammatory quiescence and vary substantially among individuals. Achieving a shared understanding, and making explicit what physicians and patients mean when referring to ‘disease activity’, ‘disease control’, or ‘remission’ is imperative and will likely require both quantitative and qualitative approaches. The study further informed about the temporal behaviour of discordance, showing that its distribution remained relatively stable over time. However, these analyses are based on group-level data and do not allow conclusions regarding individual-level stability. An important unresolved question is therefore whether discordance represents a fixed trait—potentially reflecting stable individual characteristics—or a modifiable state. It is likely that both components coexist. Interventions that are efficacious to manage domains prioritized by both physicians and patients (e.g. biologics) [6], as well as strategies aimed at improving health literacy and patient–physician communication have the potential to reduce discordance. Importantly, within the current treat-to-target paradigm, these discrepancies are not merely conceptual but have tangible consequences. A substantial proportion of patients may be considered ‘on target’ according to physician-defined metrics while still perceiving their health as suboptimal. As portrayed by patient-research partners from the Amsterdam cohort: ‘remission does not always feel like remission’. Current operationalizations of treat-to-target do not incorporate patient perspectives: SLEDAI-2K lacks patient-reported components, and PGA scoring traditionally excludes symptoms such as pain and fatigue unless they are attributable to active SLE. Addressing this discordance will require re-examining how treatment targets are defined and operationalized in SLE [7]. Potential approaches include: (1) incorporating patient-reported outcomes into targets definitions, mirroring approaches adopted in inflammatory arthropathies; (2) adopting physician-reported global disease activity instruments that integrate patient-reported symptoms, such as the existing SLAM-R, or instruments emerging from ongoing initiatives such as the TRM-SLE taskforce [8]; and (3) expanding current strategies to a multi-target framework, in which targets independent of disease activity (e.g. optimal health-related quality of life, or absence of fatigue) are explicitly pursued. A prerequisite for success will be the meaningful inclusion of patient-research partners from study inception, following structured workflows such as those recommended by EULAR [9]. Their inclusion in key initiatives—including EULAR guidelines, the OMERACT core domain set [10], and TRM-SLE [8]—represents important progress in this direction. Engaging patients in research not only enriches study design and interpretation but also ensures that findings reflect patient experiences and priorities. Ultimately, this is essential to enable a fulfilling life for all people living with lupus. No original data are presented in this article. A.G. received funding support from the Swedish Rheumatism Associaiton (R-1034702), Alexandra - för Kvinnor & Hälsa stipendiestiftelse, and Karolinska Institutet (2025–02772). Disclosure statement: The authors have declared no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Gomez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: